Enabling Technologies for the Green Synthesis of Pharmaceutical Agents
Event details
| Date | 09.06.2020 |
| Hour | 16:15 › 17:30 |
| Speaker | Dr. Rebecca Ruck Dr. Rebecca T. Ruck joined Merck Research Laboratories, Process Research & Development in 2005 and is currently Executive Director of Enabling Technologies, PR&D in Rahway, NJ. Her team is tasked with leveraging its expertise in areas such as Catalysis, Biotechnology and Flow Chemistry to enable processes for APIs in the MSD pipeline and developing new capabilities that will allow us to continue to do so into the future. Becky previously served as Director of three different teams: Process Chemistry, Catalysis & Automation and Discovery Process Chemistry. Over the course of her career, Becky and her team have impacted projects across a range of therapeutic areas, including beta-lactamase inhibitors, hepatitis C and diabetes. Becky earned her A.B. summa cum laude from Princeton University in 1998. She received a Ph.D. from Harvard University in 2003, where she was an NSF Fellow in the research group of Professor Eric Jacobsen. Following graduate studies, Becky served as an NIH post-doctoral fellow in the lab of Professor Robert Bergman at the University of California, Berkeley. She has a real passion for driving Women in Chemistry activities and was named the 2018 winner of the ACS Award for Encouraging Women into Careers in the Chemical Sciences. |
| Location | |
| Category | Conferences - Seminars |
Investment in new technologies enables the pharmaceutical industry to develop innovative and sustainable processes for the preparation of Active Pharmaceutical Ingredients. This presentation will highlight several of the new capabilities in which MSD has invested and the corresponding synthetic benefits gained. Ultimately, these innovative investments have enabled the development of creative processes now being used to prepare marketed and late stage therapeutics in an environmentally benign fashion.
Practical information
- General public
- Free